Navigation Links
Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma

or "Accentia") is a vertically integrated biopharmaceutical company focused on the development and commercialization of drug candidates that are in late-stage clinical development and typically are based on active pharmaceutical ingredients that have been previously approved by the FDA for other indications. Usually these drug candidates can access the accelerated 505(b)(2) regulatory approval pathway, which is generally less time-consuming and less expensive than the typical 505(b)(1) pathway that must be used for new chemical entities. The Company's lead product candidate is SinuNase(TM), a novel application and formulation of a known therapeutic to treat chronic rhinosinusitis. SinuNase has been granted Fast Track status by the FDA and it is currently in a pivotal Phase 3 clinical trial. During this fiscal year, the Company also plans to file an Investigative New Drug (IND) for a pivotal Phase 3 clinical trial of Revimmune, to treat numerous autoimmune diseases with an initial indication targeting refractory relapsing-remitting Multiple Sclerosis. Revimmune is based on pulsed, ultra-high dosing of a well-known chemotherapeutic agent under a risk management program. Additionally, through an investment strategy, the Company has acquired the majority ownership interest in Biovest International, Inc. ("Biovest"), (BVTI.OB) and a royalty interest in Biovest's lead drug candidate, BiovaxID(TM) and any other biologic products developed by Biovest. Biovest is currently conducting a pivotal Phase 3 clinical trial for BiovaxID which is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkin's lymphoma. BiovaxID has been granted Fast Track status by the FDA. In addition to these product candidates, the Company has a specialty pharmaceutical business which markets products focused on respiratory disease and an analytical consulting business that serves customers in the biopharmaceutical industry. For further information, visit the Company W
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
2. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
3. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
4. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
5. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
6. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
7. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New Treatment Benchmark in Patients With Metastatic Colorectal Cancer
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action
Post Your Comments:
(Date:8/22/2014)... Cali ., Aug. 22, 2014  Research presented at ... a therapy being developed by Hera Therapeutics Inc. combats three ... percent of all cervical cancer. When tested in ... HPV-16, HPV-18 and HPV-11 cells, according to Louise T. ... presented the findings at the Seattle ...
(Date:8/22/2014)... - SQI Diagnostics Inc. (TSX-V: SQD), a life ... and products for advanced microarray diagnostics, today announced ... Agreement to contract with a UK-based company to ... initial phase of this agreement, SQI will be ... one of the customer,s assays, operational on SQI,s ...
(Date:8/21/2014)... Nektar Therapeutics (NASDAQ: NKTR ... results from its Phase 3 pivotal clinical trial ... factor VIII (rFVIII) treatment for hemophilia A based ... primary endpoint in reducing annualized bleed rates (ABR) ... arm. Top-line results from the prospective, ...
Breaking Medicine Technology:Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5
... Inc. (NYSE: HSP ), a leading global specialty ... will present at the Morgan Stanley Global Healthcare Conference on ... presentation is scheduled to begin at 8:35 a.m. Eastern time ... all interested parties through a live audiocast accessible via the ...
... Wright Therapy Products, Inc. announced today that ... Executive Officer of the company.  The company, based ... devices targeted for the treatment of lymphedema, venous ... Wright Therapy after holding senior financial and sales ...
Cached Medicine Technology:Industry Leaders Hinson and Friel Join Wright Therapy Products 2
(Date:8/23/2014)... 2014 Dealing with a drug or alcohol ... the addict is a child. Adolescent addiction has been an ... time, but a new helpline is now providing a valuable ... to find a real addiction recovery center. , The Troubled ... impact in the community. By calling (404) 975-2762, parents and ...
(Date:8/22/2014)... (PRWEB) August 23, 2014 Search ... on the first page of search engines and ... SEO Hosting has recently compared many Linux hosting ... and Bluehost are the most recommended Linux hosting ... Australia and Europe to buy high quality Linux ...
(Date:8/22/2014)... Today, Zane Benefits, the #1 Online Health ... Plans. , According to Zane Benefits, employers are adopting ... the cost of healthcare without reducing coverage for employees. ... can be confusing. , The new guide contains a ... types of ABHPs. It also explains the similarities, ...
(Date:8/22/2014)... 23, 2014 This report studies ... Liquid Handling Systems), Consumables (Tubes), Kits (Isolation, Purification), ... Diagnostics) - Global Forecast to 2018" This market ... is poised to grow at a CAGR of ... million by 2018. , Browse 98 market data ...
(Date:8/22/2014)... Recently, iFitDress.com, a well-known wedding dress manufacturer and ... wedding gowns . In addition to this, the company’s ... are provided with low shipping fees. , He ... new wedding gowns. In our online store, there are ... choose from. What’s more, all of them are extremely ...
Breaking Medicine News(10 mins):Health News:Atlanta’s New Troubled Teen Helpline Is Making a Difference in the Community 2Health News:Top10BestSEOHosting.com Announces Best Cheap Hosting Suppliers Of This Summer 2Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 4Health News:Discounted Wedding Gowns For Sale At Leading Online Shop iFitDress.com 2
... harbor profound misperceptions about the effects ... designed to help them quit, PITTSBURGH, Nov. 13 ... dangers of smoking over the past 40 years, a ... GlaxoSmithKline,Consumer Healthcare, an industry leader in smoking cessation, indicates,major ...
... Disease & Kennel Cough: Serious, But Avoidable; ... Reputable Pet Sitter, BERKELEY, Calif., Nov. 13 With ... reports regarding the highly,contagious and potentially deadly strains of canine ... cough virus -- have many dog,owners worried. So, what,s a ...
... is the only way,to describe the unsolicited testimonial received this month by ... Because of your service we were there within about ... is already home as of yesterday evening. Your service ... never work for her because when she has an ...
... Inc., a subsidiary of Natural Nutrition Inc. ... made another major,breakthrough in the international market ... Panama. InterACTIVE Nutrition brand high energy protein,products ... department in Panama.,This is a significant achievement, ...
... Today; ... in the United States, LYON, France, November 13 ... it has,signed an exclusive global collaboration agreement with Acambis plc, ... help fight against,this serious, life-altering and potentially fatal disease. Scientists,believe ...
... carbohydrates may help stunt the growth of prostate tumors, according ... The study, in mice, suggests that a reduction in insulin ... , This study showed that cutting carbohydrates may slow tumor ... urologist at Duke University Medical Center and lead researcher on ...
Cached Medicine News:Health News:Smokers Remain Unaware of the Health Effects of Smoking, New Survey Finds 2Health News:Smokers Remain Unaware of the Health Effects of Smoking, New Survey Finds 3Health News:Smokers Remain Unaware of the Health Effects of Smoking, New Survey Finds 4Health News:Smokers Remain Unaware of the Health Effects of Smoking, New Survey Finds 5Health News:Smokers Remain Unaware of the Health Effects of Smoking, New Survey Finds 6Health News:Safeguard Your Pet From Seasonal Ailments 2Health News:Safeguard Your Pet From Seasonal Ailments 3Health News:Sentry Telecare Establishes Partnering Program to Market Telephone Check-in and Personal Emergency Response Service 2Health News:Natural Nutrition Ships First InterACTIVE Nutrition Brand Products to Panama 2Health News:Sanofi Pasteur and Acambis Join Forces to Bring West Nile Vaccine to Market 2Health News:Sanofi Pasteur and Acambis Join Forces to Bring West Nile Vaccine to Market 3Health News:Sanofi Pasteur and Acambis Join Forces to Bring West Nile Vaccine to Market 4Health News:A low-carb diet may stunt prostate tumor growth 2
... The Estriol (unconjugated) enzyme immunoassay (EIA) test ... in vitro,determination of unconjugated estriol in human ... The Estriol (unconjugated) procedure is an enzyme ... competitive binding. In this procedure, estriol is ...
LH EIA Reproductive Markers 025-BC-1031 Luteinizing Hormone...
... based on the competition principle and the ... in the sample and a fixed amount ... for the,binding sites of a polyclonal Estradiol ... hours incubation the microtiterplate is,washed to stop ...
... the most important androgen secreted into the ... the Leydig cells of the testes; in ... derived from,peripheral conversion of androstenedione, ca. 25% ... the adrenal glands. The Testosterone ELISA KIT ...
Medicine Products: